Compare
DiaMedica Therapeutics Inc. vs Q32 Bio Inc. vs Lifevantage Corp vs OnKure Therapeutics, Inc.
| Latest fiscal year | DiaMedica Therapeutics Inc. DMAC | Q32 Bio Inc. QTTB | Lifevantage Corp LFVN | OnKure Therapeutics, Inc. OKUR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $53.74M | $182.59M | n/a |
| Revenue growth (YoY) | n/a | n/a | -20.1% | n/a |
| Gross margin | n/a | n/a | 77.6% | n/a |
| Operating margin | n/a | 31.5% | 3.3% | n/a |
| Net margin | n/a | 55.5% | 2.8% | n/a |
| Net income | -$32.77M | $29.82M | $5.07M | -$59.52M |
| EPS (Diluted) | n/a | $2.42 | $0.40 | -$4.40 |
| Operating cash flow | -$29.06M | -$33.54M | $10.24M | -$51.83M |
| Free cash flow | -$29.10M | -$33.54M | $6.67M | -$51.87M |
| Cash & equivalents | $15.65M | $48.30M | n/a | $59.05M |
| Total assets | $61.37M | $61.78M | $62.11M | $62.12M |
| Total liabilities | n/a | $19.76M | $28.52M | $5.93M |
| Shareholders' equity | $56.11M | $42.01M | $33.59M | $56.18M |
| Return on year-end equity | -58.4% | 71.0% | 15.1% | -105.9% |
| Shares outstanding | 53.74M | 12.86M | 12.52M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | DiaMedica Therapeutics Inc. | Q32 Bio Inc. | Lifevantage Corp | OnKure Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $500.0K Ended 2018-12-31 | $53.74M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $0 Ended 2024-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $228.53M Ended 2025-06-30 | n/a |
| 2 years earlier | n/a | -$6.65M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | n/a |
| 3 years earlier | n/a | n/a | $213.40M Ended 2023-06-30 | n/a |
| 4 years earlier | n/a | n/a | $206.36M Ended 2022-06-30 | n/a |